Drug intelligence / Profile preview

humanized SMART Anti-IL-12 Antibody

Development stage: Preclinical
Lead developer: PDL BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

The humanized SMART Anti-IL-12 Antibody is a protein-based biologic developed for the treatment of autoimmune diseases. It was created by PDL BioPharma through the humanization of a murine anti-IL-12 antibody originally licensed from Hoffmann-La Roche. This antibody targets interleukin 12 (IL-12), a cytokine involved in immune regulation and implicated as a therapeutic target in autoimmune conditions. By binding to IL-12, the antibody is designed to inhibit its activity, thereby modulating immune responses that contribute to autoimmunity[1].

Targets

IL12 (Interleukin-12)

Beyond the preview

Go deeper on humanized SMART Anti-IL-12 Antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on humanized SMART Anti-IL-12 Antibody.

Explore the full profile